PALETTE- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Bayesian Basket Trial"

PALETTE is a perpetual adaptive platform to efficiently study sepsis interventions within 'treatable traits' in all-ages patients enabling prompt evaluation of pandemic treatments. Treatable traits, therapeutic targets identified by phenotypes or endotypes (defined by biological mechanism or by treatment response) through validated biomarkers (measurable characteristic reflecting normal or pathogenic processes, or treatment responses), may include multi-omics, cellular, immune, metabolic, endocrine features, or intelligent algorithms. PALETTE Bayesian adaptive design enables parallel investigations of multiple interventions for sepsis, and quick inclusion of pandemic pathogens. PALETTE's new conceptual model will respond to the challenges of standard approaches, i.e. series of sepsis trials, each investigating one or two interventions, expensive, time consuming, and inappropriate in pandemic context.

开始日期2026-04-01

申办/合作机构

Assistance Publique des Hôpitaux de Paris SA

NCT06942039

/ Not yet recruiting早期临床1期

A Pilot Study of Intrathecal Topotecan and Maintenance Chemotherapy in the Post-consolidation Setting for the Treatment of High-risk Embryonal Central Nervous System Tumours in Children Less Than 6 Years of Age

Pilot study to determine feasibility of adding intrathecal chemotherapy and maintenance therapy after high dose chemotherapy for treatment of newly diagnosed HR-EBTs in patients less than 6 years of age.

开始日期2025-06-01

申办/合作机构

C17 Council

NCT06982183

/ Recruiting临床4期IIT

The Effects of Propranolol, Hydrocortisone, and Morphine on Military-Relevant Performance Outcomes: A Randomized, Blinded, Placebo Controlled Study

This clinical trial aims to evaluate the nature and duration of effects of three FDA-approved medications (propranolol, hydrocortisone, and morphine) on military-relevant cognitive, emotional, and motor performance following an exposure to a stressful situation (i.e., exposure to a tarantula) in physically healthy adult volunteers (aged 18 - 40) with fear of spiders to help the future development of medications for treating Acute Stress Reactions.
The main questions this study aims to answer are:
Will placebo treatment (oral placebo) result in significant decrements in Psychomotor Vigilance Task (PVT) performance compared to propranolol treatment?
Will placebo treatment [intramuscular (IM) placebo] result in significant decrements in PVT performance compared to hydrocortisone treatment?
Will placebo treatment (IM placebo) result in significant decrements in PVT performance compared to morphine treatment?
Participants will receive one of five study medications (oral propranolol, oral placebo, IM hydrocortisone, IM morphine, or IM morphine) after a brief exposure to a tarantula. Participants will complete cognitive and simple motor tasks and psychological assessments before and after the study medication administration.

开始日期2025-05-01

申办/合作机构

Walter Reed Army Institute of Research

100 项与醋酸氢化可的松相关的临床结果

登录后查看更多信息

100 项与醋酸氢化可的松相关的转化医学

登录后查看更多信息

100 项与醋酸氢化可的松相关的专利（医药）

登录后查看更多信息

3,090

项与醋酸氢化可的松相关的文献（医药）

2025-06-01·JOURNAL OF HAZARDOUS MATERIALS

Pollution characteristics, sources and ecological risks of steroid hormones in Fangchenggang Bay, South China Sea: Significant impacts of rivers and domestic sewage entering the sea

Article

作者: Fang, Qin ; Ren, Chaoxing ; Long, Huiqin ; Gao, Guilan ; Liu, Fangfang ; Lan, Wenlu

The characteristics, sources and ecological risk of steroid hormone pollution were investigated at 14 stations in Fangchenggang Bay. The results revealed that the detection rate of the steroid hormones in both seawater and sediment was 100 %. Twenty-four types of steroid hormones were detected in seawater, and the concentrations ranged from 0.05 (P) to 7.40 ng/L (HCT). Seventeen types of steroid hormones were detected in marine sediments, and the concentrations ranged from 0.02 (SZL) to 0.82 ng/g (E3). The monthly contributions of rivers flowing into the sea and domestic sewage treatment plants were 2178.2 kg and 46.03 kg, respectively. Based on the ecological risk assessment results, MT and EE2 in seawater were considered to be at high risk level, and E2α was at medium risk, whereas the others were considered to be low or no risk levels; in marine sediments, MT, E2αand EE2 were at a high risk level; AED, E1, E2 α, and E3 were at a medium risk level; and the others were at low or no risk levels. The steroid hormones in the monitoring area were mainly affected by land-based pollution. This issue warrants immediate attention from the relevant management departments, and effective preventive measures need to be performed.

2025-04-01·Minerva Surgery

Clinical evidence and rationale of topical nifedipine and lidocaine ointment in the treatment of anal fissure and hemorrhoidal disease

Review

作者: Trompetto, Mario ; Gallo, Gaetano

INTRODUCTION:

Anorectal conditions such as hemorrhoidal disease and anal fissure are frequently painful and debilitating. Pain after hemorrhoidectomy is also common and distressing. These conditions are at least initially managed conservatively. An ointment formulation containing the calcium channel blocker nifedipine and the local anesthetic lidocaine has an established role in the treatment of rectal conditions, particularly conditions associated with anal sphincter hypertonia such as hemorrhoidal disease and anal fissure. This review aimed to compile the evidence for the use of nifedipine 0.3% and lidocaine 1.5% ointment in treating these common but bothersome anorectal diseases.

EVIDENCE ACQUISITION:

A comprehensive literature search was conducted, updated to 07 August 2024, using PubMed and MEDLINE databases to identify studies of lidocaine and nifedipine, alone or in combination, for the topical treatment of anal fissure or hemorrhoidal disease. Articles identified in the literature search were supplemented by ad hoc searches and supplemented by relevant literature known to the authors.

EVIDENCE SYNTHESIS:

Nifedipine 0.3% and lidocaine 1.5% ointment is effective in relieving pain and aiding the resolution of thrombosed hemorrhoids, reducing resting anal pressure and healing chronic anal fissures, and controlling pain after hemorrhoidectomy. The ointment was significantly better than controls consisting of topical lidocaine 1.5% alone or in combination with hydrocortisone acetate 1%.

CONCLUSIONS:

Although the available literature on the topical application of nifedipine and lidocaine in anorectal diseases is limited, nifedipine 0.3% and lidocaine 1.5% ointment should be considered a valid treatment option for clinicians treating anorectal diseases. Further studies are warranted to confirm and extend the results reported.

2025-04-01·Journal of Environmental Chemical Engineering

Development of scalable cultivation strategy for microalgal biomass generation using wastewater and integrated biorefinery approach for biofuel production

作者: Jagadale, Krushna ; Tilva, Jeel ; Singh, Bhaskar ; Gawali, Sushant ; Guldhe, Abhishek ; Alam, Shahrukh Nawaj

Microalgal biomass production using wastewater (WW) is a sustainable approach for economically viable biorefinery.The present study aims to develop a scalable cultivation strategy using novel microalgae strain Marvania coccoides for biofuels productionThe cultivation strategy based on nutrient supplementation is developed at lab-scale (1 L) and validated at open-raceway pond system (200 L).Nutrient-supplemented wastewater (OWW) showed higher biomass productivity at both lab-scale (87.36 mg.L-1.d-1) and open pond system (133.89 mg.L-1.d-1) as compared to synthetic media.Biodiesel yield of 92.30 % was achieved upon transesterification of lipids from OWW (200 L) medium.Moreover, the residual biomass, i.e., lipid-extracted microalgal (LEM) biomass, yielded in 26.65 % of bio-oil and 56.94 % of biochar upon non-catalytic pyrolysis.Bio-oil and biochar produced were analyzed using element analyzer, gas chromatog.-mass spectrometry (GC-MS), and fourier-transform IR spectroscopy (FTIR).This scalable cultivation strategy for microalgae and biorefinery approach for production of biodiesel, bio-oil and biochar is sustainable solution for managing wastes and generation of biofuels.

项与醋酸氢化可的松相关的新闻（医药）

2025-02-04

·Business Wire

Devonian Health Group Inc. Reports Superior Anti-Inflammatory Potency of Thykamine™ in Comparative In Vitro Study

QUEBEC CITY--( BUSINESS WIRE )--Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, today announced the results of its in vitro comparative study, which demonstrate the anti-inflammatory effect of Thykamine™, with superior potency on the inflammatory biomarkers as compared to currently marketed anti-inflammatory agents, which included various corticosteroids and a phosphodiesterase inhibitor. The assays were conducted at Department of Microbiology, Infectious Diseases, and Immunology in the Faculty of Medicine at Université Laval (Quebec City) under the leadership of Pr Louis Flamand, PhD, MBA (1) in collaboration with Dr John Sampalis, PhD, Epidemiologist, Medicine Faculty, McGill University and Dr Charles Lynde, MD from Lynde Dermatology and Associate Professor in the Department of Medicine at the University of Toronto. The primary objective of the study was to compare the anti-inflammatory potency of Thykamine™ to other anti-inflammatory agents in the market, specifically betamethasone valerate, clobetasol, crisaborole, 21-acetate hydrocortisone, pimecrolimus and prednisone. The experiment involved treating lipopolysaccharide (LPS) stimulated U937 monocytic cells with each agent. Anti-inflammatory potency was assessed by the percent inhibition of the activity of four cytokines induced by each agent. The four cytokines tested were MCP-1, MIP-1α, MIP-1β and RANTES that have been implicated in several autoimmune diseases. Percent inhibition was calculated as the reduction in lipopolysaccharide (LPS) induced cytokine activity after addition of the agent. Given that the aim of anti-inflammatory drugs is to dampen cytokine induced inflammation, these results can be used as inference to overall anti-inflammatory efficacy. All agents were tested at four increasing concentrations except for pimecrolimus that was tested at three concentrations. All culture conditions were run in hexaplicate (n=6). Cell-free supernatants were collected and immediately assayed for cytokine concentration using Pro-Carta 6 plex (Life Technologies). U937 secreted amounts of IL-6 or IL-10 that were below the detection limits of the assay and were not included in the analyses. When compared to the other agents, Thykamine™ showed clinically important and statistically significant higher inhibition potency for MCP-1 (by 28% to 136%; P< 0.009), MIP-Alpha (by 30% to 108%; P < 0.001), MIP-1 Beta (by 39% to 111%; P < 0.001). For RANTES higher inhibition was observed for all agents (by 47% to 258%) except for Crisaborole and Prednisone. In this assay, pimecrolimus did not inhibit any of the cytokine tested. “ These results support the wide spectrum anti-inflammatory properties of Thykamine™ with potency that is superior to currently marketed anti-inflammatory agents. This study indicates a multi mode of action of Thykamine™ affecting several cytokines and other biomarkers, supporting the clinical efficacy demonstrated in phase 2 studies in ulcerative colitis and atopic dermatitis in adults,” said Dr Louis Flamand, lead study investigator. “ The high potency and previously established clinical efficacy of Thykamine™ , combined with its placebo-like safety, should compel practitioners to consider its use as a first line treatment, especially with the potential safety concerns of the present standard of care,” said Dr Lynde, who was consulted on the current study and was the lead investigator in Devonian’s phase 2 study in adults with mild-to-moderate atopic dermatitis. The study’s co-investigator Dr. John Sampalis, Clinical Epidemiologist, and Professor of Medicine at McGill with extensive experience in the evaluation of treatments for autoimmune disorders commented: “ The results of this in vitro study are extremely encouraging. The favorable safety profile of Thykamine™ as demonstrated in human clinical studies and its high anti-inflammatory potency proven in this study, would position Thykamine™ as a possible first line treatment of choice for several autoimmune conditions in the early stages of the disease. This can result in steroid sparing effect and reduced need for aggressive treatments with biologics and other immune modulators, that are associated with serious side effects and long term negative consequences.” Investigators of this study are planning to submit the results in a peer-reviewed journal. (1) Pr. Louis Flamand is a director on the board of directors of the Corporation About Thykamine™ Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a large phase II study in adult patients with mild-to-moderate Atopic Dermatitis. Both Thykamine™ and SUPREX™ platform are protected by several patents in North America, Europe and Asia. About Devonian Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare Inc., focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’. Devonian is traded publicly on the TSX Venture Exchange (the “Exchange”) (TSXV: GSD) and on OTCQB exchange (OTCQB: DVHGF). For more information, visit www.groupedevonian.com Cautionary Note Regarding Forward-Looking Statements All statements, other than statements of historical fact, contained in this press release including but, not limited to those relating to the economical impact of clinical study, the efficiency of the high anti-inflammatory potency proven and the position of the Thykamine™ as a possible first line treatment of choice for several autoimmune conditions in the early stages of the disease and the reduced need for aggressive treatments with biologics and other immune modulators, that are associated with serious side effects and long term negative consequences, and, generally, the above “About Devonian” and “About Altius” paragraphs, which essentially describes the Corporation’s outlook, constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

临床2期临床结果

2025-01-09

·PRNewswire

Cristcot Announces Positive Phase 3 Results for Novel Hydrocortisone Acetate Suppository Administered with the Sephure® Suppository Applicator for the Treatment of Ulcerative Colitis of the Rectum

Pivotal Phase 3 Data Met Pre-defined Outcomes - Achieving a Clinical Response by Day 15 and Clinical Remission by Day 29 On Track for NDA Submission in Q1 2025 CONCORD, Mass., Jan. 9, 2025 /PRNewswire/ -- Cristcot, a clinical-stage pharmaceutical company advancing innovative therapies for gastrointestinal diseases, today announced positive topline results from its pivotal Phase 3 cessa clinical trial evaluating its novel hydrocortisone acetate (HCA) suppository administered with the Sephure® suppository applicator in patients with ulcerative colitis (UC) of the rectum. The cessa Phase 3 trial was constructed to evaluate the safety and efficacy of Cristcot's investigational HCA suppository formulation designed to halt acute flares in UC. The study examined the treatment for use alone as monotherapy or with other maintenance therapies (e.g., 5-ASAs, biologics, anti-TNFs, Jak inhibitors, etc.). Key Phase 3 Study Results : The cessa Phase 3 trial randomized 171 patient subjects, meeting the study protocol criteria, who were experiencing moderate to severe active UC of the rectum at the time of enrollment. The study was conducted at multiple research sites around the world and patient subjects were randomized to receive either once-daily (QD), twice-daily (BID) dosing of the 90 mg hydrocortisone acetate suppository or placebo for 28 days, followed by a 10-day taper period. Primary Endpoint: Clinical Remission by Day 29 (Visit 7) The trial achieved its primary endpoint of clinical remission, defined as a Modified Mayo Score of 0-2, which includes rectal bleeding sub-score of 0, reduction of stool frequency from baseline with sub-scores of 0 or 1 and mucosal healing as determined by an endoscopic sub-score of 0 or 1. In the once-daily (QD) treatment arm, 23.0% of patients achieved clinical remission by Day 29. In the twice-daily (BID) treatment arm, 17.5% of patients achieved clinical remission by Day 29. When pooling both treatment active treatment arms, 20.2% of patients receiving active treatment reached clinical remission, compared to only 2.1% in the placebo group, demonstrating a statistically significant benefit. Secondary Endpoints: Clinical Response by Day 15 (Visit 5) Rapid clinical response for both, rectal bleeding = 0 and reduction of stool frequency = 0 or 1, was observed in both active treatment arms by Day 15. Safety Profile The treatment was well-tolerated, with no adverse events of statistical significance reported across treatment arms. Side effects observed were generally mild and consistent with those typically associated with corticosteroid use. Patient Compliance Notably, the trial demonstrated high compliance rates across treatment arms, with 97% compliance for the once-daily regimen. "UC patients are urgently in need of a therapeutic option to manage intermittent and acute flares, inherent in the disease profile, as current therapies often take several months to induce clinical response and up to 52 weeks to achieve remission," said Jennifer Davagian, Founder and Chief Executive Officer, Cristcot. "During the first quarter of 2025 we will be finalizing our NDA submission as we continue to build our manufacturing and commercial capabilities to bring this potentially transformative therapy to patients in the U.S. We are also evaluating marketing partnerships that would help accelerate the commercialization of the drug to market. We look forward to providing further updates in the coming months." "Subject to FDA approval, the ability for patients to achieve symptomatic relief in as little as two weeks and clinical remission in just four weeks will be a significant advancement for UC patients," added Dr. Monika Fischer, MD, MSc, FACG, AGAF, Chief Fellow in the Division of Gastroenterology and Hepatology, Indiana University Department of Medicine. "This novel therapy is positioned to fill a critical gap in the treatment of ulcerative colitis and possibly related conditions. A novel topical steroid therapy can allow physicians to better manage acute crisis episodes and/or transition patients from one maintenance therapy to another, while reducing the burden to both patients and payers. These results demonstrate Cristcot's potential to transform how we approach flare management and change the treatment paradigm for ulcerative colitis. Cristcot's new product is a potential new best-in-class therapy that delivers better efficacy through its unique release and absorption profile." About the cessa Trial This pivotal Phase 3 trial was designed to evaluate the safety and efficacy of Cristcot's hydrocortisone acetate 90-milligram suppository in patients with ulcerative colitis of the rectum. This was a randomized, multi-center, double-blind, three arm placebo-controlled study in male and non-pregnant, non-lactating female subjects aged 18 years and older. Conducted across multiple global sites, the trial enrolled 784 patient subjects with 171 meeting the criteria of the protocol who received twice-daily dosing of the suppository for 28 days, followed by a 10-day taper period. The study's primary endpoint was clinical remission at Day 29, defined by a Modified Mayo score of 0-2 including zero bleeding, reduction of stool frequency and mucosal healing. Secondary endpoints included rapid symptom relief, with significant clinical response of a reduction in both bleeding and stool frequency observed as early as Day 15. Baseline Characteristics: Male or non-pregnant, non-lactating females aged 18 years and older. Subjects with a confirmed diagnosis of UC with an endoscopic score 2-3 extending no further than 15 centimeters (cm) from the anal verge as assessed by endoscopic procedure performed at Visit 2. Note: Subjects may have a history of more extensive UC (e.g., pancolitis), but have an endoscopic score of 2-3 only in the rectum at the time of the screening endoscopy (endoscopic score 0-1 beyond 15 cm from the anal verge is not exclusionary). Modified Mayo sub-score for stool frequency of 1-3. Modified Mayo sub-score for rectal bleeding of 0-2. Modified Mayo endoscopic sub-score of 2-3. Total Modified Mayo Score (without physician global assessment) of 4-8. About Cristcot's HCA Suppository Cristcot's investigational HCA suppository formulation is a novel therapy delivered using the Sephure® suppository applicator, the small-volume suppository ensures precise placement, minimizing discomfort and leakage. This innovative delivery system may likely enhance patient compliance. Unlike traditional corticosteroid treatments, the suppository's differentiated mechanism of action allows for rapid metabolism and localized efficacy, reducing systemic exposure. About Ulcerative Colitis UC is a life-long, chronic gastrointestinal autoimmune disease characterized by inflammation and ulcers in the lining of the large intestine, including the rectum and sometimes, all or part of the colon. Symptoms often include rectal bleeding, profuse diarrhea, bowel urgency, tenesmus, and abdominal pain significantly impacting patients' quality of life. UC flares originate in the rectum, and untreated inflammation can progress to more extensive disease, leading to hospitalization or surgery. There is no cure for UC and breakthrough flares, even while taking maintenance medication, is a known characteristic of the disease profile. Over 55% of UC patients experience 3-5 flares annually, with many reporting debilitating effects on daily activities, work, and mental health. Despite existing treatments, patients experience intermittent flares and often change therapies as a measure to treat increased disease activity. The time of transition between one treatment to another is further complicated while waiting for the new therapy to reach full efficacy potential. Gaps remain in addressing flares quickly and effectively, highlighting the need for targeted therapies that can provide rapid symptom relief and remission. About Cristcot Cristcot is a clinical-stage pharmaceutical company dedicated to advancing targeted therapies for gastrointestinal diseases. The Company's lead asset, a novel hydrocortisone acetate suppository, is positioned to become the first line therapy for ulcerative colitis. . Cristcot's diversified pipeline includes investigational development programs for ulcerative colitis, acute pancreatitis, hemorrhoid disease and other inflammatory gastrointestinal indications with an emphasis on innovative, patient-centric solutions. The company is headquartered in Austin, Texas. For more information, please visit and connect with us Linkedin. Forward-Looking Statements Certain information set forth in this press release contains "forward-looking information", including "future-oriented financial information" and "financial outlook", under applicable securities laws (collectively referred to herein as forward-looking statements). Example of forward-looking statements include, but are not limited to, the (i) projected financial performance of the Company; (ii) market prospects and potential future sales for the Company products; (iii) expected development of the Company's products, business and projects; (iv) availability of competing products in the market; (v) prospects for regulatory approval of the Company's products; (vi) execution of the Company's vision and growth strategy; and (vii) availability of protections under applicable intellectual property laws. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Although forward-looking statements contained in this press release are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. Contacts Mark C. Ensign, COO/CSO [email protected] Tanner Kaufman / Shana Marino FTI Consulting [email protected] / [email protected] SOURCE Cristcot WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果临床3期申请上市

2024-07-14

·药精通Bio

行业研究 | 生物制药十巨头的多肽药物名录（附结构图）

深度聚焦多肽、多肽偶联药物研发、质控、工艺开发，展位咨询&免费入场券：联系电话181 1603 6798，扫码立即获取免费入场券：文章来源：多肽圈｜中肽生化内容团队编辑根据2024年4月15日的市值排行榜，全球前十名的生物制药公司所拥有的多肽/拟肽资产如下： 01 礼来（7146.3亿美元） Tirzepatide · Mounjaro (tirzepatide)：2型糖尿病，2022年5月13日获批 · Zepbound (tirzepatide)：肥胖症，2023年11月8日获批 · Forteo (Teriparatide)：骨质疏松症，2022年11月26日获批 Teriparatide 02 诺和诺德（5645.6亿美元） Semaglutide · Wegovy (semaglutide)：肥胖症，2021年6月4日获批 · Rybelsus (semaglutide)：2型糖尿病（口服），2019年9月20日获批 · Ozempic (semaglutide)：2型糖尿病，2017年12月5日获批 · Victoza (liraglutide)：2型糖尿病，2010年1月25日获批 · Saxenda (liraglutide)：肥胖症，2014年12月23日获批 Liraglutide 03 强生（3554.9亿美元）无上市多肽资产 04 默沙东（3185.0亿美元） · CANCIDAS® (caspofungin acetate，环肽): 棘白菌素类抗真菌药物，针对对其他抗真菌药物难治或不耐受的侵袭性曲霉菌病成人患者，2001年1月26日获批。 caspofungin · CUBICIN® (daptomycin for injection，环肽)：脂肽抗生素，用于治疗由革兰氏阳性菌引起的全身性和危及生命的感染，2023年9月12日获批。 Daptomycin · ZEPATIER（Grazoprevir环肽+ elbasvir）: 丙型肝炎，第二代丙型肝炎病毒蛋白酶抑制剂，2016年1月28日获批。 · ZERBAXA (ceftolozane环肽 and tazobactam)：复方抗生素药物，用于治疗成人复杂性尿路感染和复杂性腹腔内感染。Ceftolozane 是一种头孢菌素抗生素（β-内酰胺类），开发用于治疗对常规抗生素耐药的革兰氏阴性菌感染。2014年12月19日获批。 ceftolozane 05 艾伯维（2873.4亿美元）无上市多肽药物 06 阿斯利康（2137.1亿美元） · Zoladex (goserelin acetate implant)：用于抑制性激素（睾酮和雌激素）产生的药物，用于乳腺癌和前列腺癌的治疗。它是一种可注射的促性腺激素释放激素激动剂（GnRH 激动剂）。1989年12月29日获批。 Goserelin · Bydureon (exenatide)：2型糖尿病。2012年1月27日获批。 · Byetta (exenatide injection)：2型糖尿病。2005年4月28日获批。 exenatide · Symlin (pramlintide acetate)：用于治疗糖尿病（1 型和 2 型）的注射胰淀素类似物药物。2005年3月16日获批。 · Zestril (lisinopril dihydrate)：血管张力素转化酶抑制剂（ACE抑制剂）药物，用于治疗高血压、心脏衰竭和心肌梗塞。2003年1月7日获批。 Lisinopril · ARGATROBAN (argatroban injection, solution)：直接凝血酶抑制剂，用于预防或治疗肝素诱导的血小板减少症（HIT）患者的血栓形成。2000年6月30日获批。 Argatroban 07 罗氏（1986.6亿美元）无上市多肽药物 08 诺华（1934亿美元） · Cibacen® (benazepril hydrochloride)：治疗高血压、心力衰竭和糖尿病肾病，1999年6月16日获批。 Benazepril · Locametz (gallium Ga 68 gozetotide)：放射性药物，由与前列腺特异性膜抗原 (PSMA) 靶向配体 Glu-Urea-Lys(Ahx)-HBED-CC缀合的 68Ga 制成，用于通过正电子发射断层扫描 (PET) 对前列腺癌进行成像。2022年3月23日获批。 Gallium Ga 68 gozetotide（图片来源：Wikipedia） · Lutathera (lutetium Lu 177 dotatate, 环肽): 镥元素放射性同位素与 DOTA-TATE 的螯合复合物，用于肽受体放射性核素治疗 (PRRT)。用于治疗患有胃肠胰神经内分泌肿瘤 (GEP-NET) 的成人癌症，这些肿瘤对激素受体生长抑素呈阳性。2018年1月26日获批。 Lutetium Lu 177 dotatate（图片来源：Wikipedia） · Neoral/Sandimmune (cyclosporine环肽, USP Modified): 强效免疫抑制剂，用于治疗类风湿性关节炎、狼疮、牛皮癣和其他自身免疫性疾病。1995年7月获批。 Cyclosporine A · NETSPOT (gallium Ga 68 dotatate injection)：Ga 68 dotatate 注射液与 PET 扫描（正电子发射断层扫描）结合使用，可定位成人和儿童的生长抑素受体阳性神经内分泌肿瘤 (NET)。 · Pluvicto (lutetium Lu 177 vipivotide tetraxetan)：用于接受了雄激素受体 (AR) 途径抑制和紫杉醇类化疗治疗的成年患者，患有前列腺特异性膜抗原（PSMA）阳性的转移性去势抵抗性前列腺癌（mCRPC）。 lutetium Lu 177 vipivotide tetraxetan（图片来源：Wikipedia） · Sandostatin (octreotide acetate环肽): 用于治疗产生生长激素的肿瘤 (例如肢端肥大症和巨人症)。1998年11月25日获批。 Octreotide 09 辉瑞（1463.3亿美元） · ACCUPRIL (quinapril HCI) · ACCURETIC® (quinapril HCl/hydrochlorothiazide)：Quinapril用于治疗高血压、心力衰竭和糖尿病肾病。它是高血压的一线治疗方法。 Quinapril · ALTACE (ramipril)：Ramipril是一种 ACE 抑制剂类药物，用于治疗高血压、心力衰竭和糖尿病肾病。它还可以用作 55 岁以上患者的预防药物，以降低高危患者（例如一些糖尿病患者和血管疾病患者）心脏病发作、中风或心血管死亡的风险。 Ramipril · AMPICILLIN FOR INJECTION (Ampicillin Sodium)：Ampicillin是一种抗生素，属于青霉素家族的氨基青霉素类。用于预防和治疗多种细菌感染，如呼吸道感染、尿路感染、脑膜炎、沙门氏菌病和心内膜炎。它还可用于预防新生儿 B 族链球菌感染。它可以口服、肌肉注射或静脉注射。 Ampicillin · BIVALIRUDIN (bivalirudin)：比伐卢定（Bivalirudin）是一种特异性、可逆的直接凝血酶抑制剂 (DTI)。它是天然药物水蛭素的合成同系物，水蛭素存在于药用水蛭的唾液中。它是一种短肽，是一种有效且高度特异性的凝血酶抑制剂，可抑制循环凝血酶和凝块结合凝血酶，同时还抑制凝血酶介导的血小板活化和聚集。用于治疗肝素诱导的血小板减少症并预防经皮冠状动脉介入治疗期间的血栓形成。 · BLEOMYCIN：Bleomycin（博来霉素）是一种来自轮枝链霉菌的相关糖肽抗生素复合物。适应症包括霍奇金淋巴瘤、非霍奇金淋巴瘤、睾丸癌、卵巢癌和宫颈癌等。通常与其他癌症药物一起使用，通过肌肉注射、皮下注射或静脉注射。它抑制 DNA 代谢并用作抗肿瘤药物，尤其是实体瘤。 Bleomycin · CEFAZOLIN (cefazolin)：头孢唑林（Cefazolin）是一种用于治疗多种病原细菌的抗细菌药，尤其针对蜂窝组织炎、泌尿道感染、肺炎、心内膜炎、败血性关节炎及胆道发炎等疾病，也可用来预防手术前或手术中B群链球菌感染。 Cefazolin · CEFEPIME (Cefepime) · MAXIPIME (cefepime hydrochloride)：Cefepime（头孢吡肟）是第四代头孢菌素类抗生素。头孢吡肟对革兰氏阳性菌和革兰氏阴性菌具有更广泛的活性，比第三代药物对这两种类型的生物体的活性更强。 Cefepime · CEFOBID (cefoperazone sodium)：cefoperazone（头孢哌酮）是第三代头孢菌素抗生素。它是少数能有效治疗对这些抗生素耐药的假单胞菌感染的头孢菌素抗生素之一。 Cefoperazone · CEFTRIAXONE (ceftriaxone)：头孢曲松（ceftriaxone）是一种第三代头孢菌素抗生素，用于治疗多种细菌感染，包括中耳感染、心内膜炎、脑膜炎、肺炎、骨和关节感染、腹内感染、皮肤感染、尿路感染、淋病和盆腔炎。 ceftriaxone · CORTISPORIN (neomycin and polymyxin B sulfates, and hydrocortisone acetate)：新霉素/多粘菌素 B/氢化可的松以 Otosporin 品牌销售，是一种用于治疗外耳炎和某些眼部疾病的药物。 Polymyxin B (多粘菌素 B，环肽) 可以单独以Poly-Rx 等商品名出售，是一种用于治疗脑膜炎、肺炎、败血症和尿路感染的抗生素。虽然它对许多革兰氏阴性感染有用，但对革兰氏阳性感染没有用。Polymyxin B由Polymyxin B1和B2两种环肽组成。 Polymyxin B1（左）和Polymyxin B2（右） · NEOSPORIN G.U. Irrigant (neomycin sulfate – polymyxin B sulfate) · NEOSPORIN Ophthalmic Solution (neomycin and polymyxin B sulfates, and gramicidin)：新孢菌素滴眼液由新霉素/多粘菌素B/杆菌肽组成，适用于局部治疗敏感细菌引起的外眼及其附件的浅表感染。此类感染包括结膜炎、角膜炎和角结膜炎、睑缘炎和睑结膜炎。杆菌肽（gramicidin），也称为杆菌肽 D，是离子载体抗生素杆菌肽 A、B 和 C 的混合物，分别占混合物的 80%、5% 和 15%。每种都有 2 种isomer，因此混合物有 6 种不同类型的杆菌肽分子。它们可以从短芽孢杆菌土壤细菌中提取。杆菌肽是含有 15 个氨基酸的线性肽，不同于不相关的杆菌肽 S，后者是一种环肽。 · DAPTOMYCIN (daptomycin，环肽)：达托霉素（Daptomycin）是一种脂肽抗生素，用于治疗由革兰氏阳性菌引起的全身性和危及生命的感染。 Daptomycin · ENALAPRILAT (enalaprilat)：Enalaprilat (依那普利拉) 是enalapril (依那普利) 的活性代谢物。它是ACE 抑制剂，是一种抗高血压药，用于在口服治疗不可行时治疗高血压。 Enalapril和Enalaprilat · ERAXIS (anidulafungin，环肽)：Anidulafungin（阿尼芬净）是一种半合成棘白菌素，用作抗真菌药物。当与伏立康唑联合使用时，它还可能用于治疗侵袭性曲霉菌感染。它是棘白菌素类抗真菌药物的一员。其作用机制是抑制 (1→3)-β-D-葡聚糖合酶，后者是一种对真菌细胞壁合成很重要的酶。 Anidulafungin · PAXLOVID (nirmatrelvir and ritonavir)：Paxlovid是由nirmatrelvir和ritonavir两种成分组成的抗SARS-Cov-2病毒口服药，其中nirmatrelvir是活性成分，为拟肽分子，是3C 样蛋白酶抑制剂。 Nirmatrelvir · PIPERACILLIN AND TAZOBACTAM (piperacillin and tazobactam)：Piperacillin (哌拉西林)和tazobactam (他唑巴坦) 联合疗法用于治疗身体许多不同部位（例如胃或肠、肺、皮肤、女性生殖器官）的细菌感染。哌拉西林和他唑巴坦组合是抗生素，属于青霉素和 β-内酰胺酶抑制剂药物组。 Piperacillin · SYNAREL (nafarelin acetate)：Nafarelin是一种促性腺激素释放激素激动剂（GnRH 激动剂）药物，用于治疗子宫内膜异位症和青春期早期。它还用于治疗子宫肌瘤、控制体外受精 (IVF) 中的卵巢刺激，以及作为变性激素治疗的一部分。 Nafarelin · SYNERCID I.V. (quinupristin环肽/dalfopristin)：Synercid I.V.（奎奴普丁和达福普丁）是一种复方抗生素，用于治疗血液和其他身体系统的严重感染。 Quinupristin · TAZICEF (ceftazidime)：头孢他啶（ceftazidime）是第三代的头孢菌素抗生素。 ceftazidime · Vancomycin Hydrochloride：盐酸万古霉素是一种抗菌处方药，用于治疗某些细菌感染，例如由艰难梭菌和金黄色葡萄球菌引起的感染。艰难梭菌和金黄色葡萄球菌是可引起 HIV 机会性感染 (OIs) 的细菌。OIs是一种与免疫系统健康的人相比，拥有较弱免疫系统的人（例如艾滋病毒感染者）发生的频率更高或更严重的感染。 10 安进（1432.4亿美元） · Kyprolis (carfilzomib)：Carfilzomib是一种选择性蛋白酶体抑制剂的抗癌药物。 Carfilzomib · Parsabiv (Etelcalcetide)：Etelcalcetide是一种拟钙药物，用于治疗血液透析患者的继发性甲状旁腺功能亢进症。Etelcalcetide 通过结合并激活甲状旁腺中的钙敏感受体发挥作用。 Etelcalcetide END 免责声明：本文信息来源于网络，本文仅作知识交流与分享及科普目的，不涉及商业宣传，不作为相关医疗指导或用药建议。文章如有侵权请联系删除。深度聚焦多肽、多肽偶联药物研发、质控、工艺开发，7月相约苏州，联系电话18116036798上下滑动查看议程 7月25日上午：主会场多肽药物蓝海布局 9:00-9:30 李学臣，香港大学化学系理学院副院长多肽药物和蛋白偶联的新策略 9:00-9:30 王珠银，深圳肽盛生物科技有限公司董事长 3D结构多肽库的构建和靶向穿膜肽筛选 9:30-10:00 马亚平，深创生物董事长靶向核素药物研究与开发 10:30-10:50 茶歇&交流 10:50-11:20 徐寒梅，中国药科大学教授；南京安吉生物科技有限公司创始人新靶点多肽药物发现及PDC药物研究进展 11:20-11:50 钱海，中国药科大学理学院院长兼药物科学研究院新药研究中心主任话题确认中 11:50-12:20 圆桌讨论：多肽药物脱颖而出的关键、未来如何保持高热度、内卷何时到来？刘东舟，华东医药首席科学官/创新药全球研发中心总经理容明强，成都佩德生物医药有限公司董事长马亚平，深创生物董事长王珠银，深圳肽盛生物科技有限公司董事长邵军，同宜医药（苏州）有限公司首席技术官部分嘉宾确认中 12:20-14:00 午餐&休息 7月25日下午：论坛一多肽药物研发进展 14:00-14:30 周建伟，南京医科大学教授/南京明人医药科技有限公司创始人基于JWA基因的多肽创新药研究 14:30-15:00 容明强，成都佩德生物医药有限公司董事长基于生存策略的动物毒素多肽新药开发 15:00-15:30 江苏万略医药科技有限公司话题确认中 15:30-15:50 茶歇&交流 15:50-16:20 韩俊峰，上海贺普药业股份有限公司总裁贺普拉肽研究进展 16:20-16:50 方小翠,国家纳米科学中心,高级工程师肿瘤免疫治疗用靶向溶瘤多肽的药物转化 16:50-17:20 张晓君，石药集团北京研究院制剂四所所长多肽药物长效递送研发进展 7月25日下午：论坛二多肽药物质控与生产 14:00-14:30 邵军，同宜医药（苏州）有限公司首席技术官多肽类药物工艺与质量控制要点 14:30-15:00 姜建军，江苏诺泰澳赛诺生物制药有限公司，多肽事业部总经理/集团副总经理/研究院副院长多肽药物合成新工艺 15:00-15:30 大西弘晃，三菱化学株式会社 Purification of Cyclic Peptide and Its Analogues with Polymeric Separation Media 15:30-15:50 茶歇&交流 15:50-16:20 李子刚，北京大学深圳研究生院，化学生物学与生物技术学院执行院长/深圳湾实验室，坪山生物医药研发转化中心主任新颖稳定多肽方法学开发及其在多肽药物开发中的应用 16:20-16:50 苏贤斌，南京工业大学教授、博士生导师连续流动绿色多肽合成（拟定） 16:50-17:20 刁星星，中国科学院上海药物研究所研究员，课题组长/苏州锐迪欧医药科技有限公司创始人新类型药物PDC LN005体外、体内代谢研究策略 7月26日上午：论坛一多肽药物研发进展 9:00-9:30 陈小新，广东众生睿创生物科技有限公司联合创始人、董事、总裁基于GLP-1的单分子多重受体激动剂治疗肥胖和NASH的研究进展 9:30-10:00 谢天，甘李药业股份有限公司，医学事务部负责人 GLP-1研发的挑战与布局 10:00-10:30 温晓芳，浙江道尔生物科技有限公司副总裁 GLP-1/GCG/FGF-21三靶点激动剂在NASH中的临床前开发 10:30-10:50 茶歇&交流 10:50-11:20 景书谦，鸿运华宁（杭州）生物医药有限公司创始人、董事长兼首席执行官 GLP药物研发进展及商业化前景 11:20-11:50 夏帅，复旦大学基础医学院青年研究员广谱抗冠状病毒多肽类融合抑制剂的研究 11:50-14:00 午餐&休息 14:00-14:30 张传亮，青岛科技大学化工学院，副教授长效降糖减重药物的差异化开发：基于BH3模拟肽的PTP1B/TC-PTP抑制剂/降解剂的设计与研发 14:30-15:00 韩智豪，中国药科大学特聘副研究员，硕士生导师基于仿生多肽的放射性药物研究 15:00-15:30 杨浩哲，香港交易所，环球上市服务部助理副总裁香港交易所助力医药企业融资上市 7月26日上午：论坛二多肽药物质控与生产 9:00-9:30 丁伟，南京知和医药科技有限公司副总，多肽首席科学家多肽药物质量研究中的常见问题与解决方案 9:30-10:00 刘磊，江苏大学材料科学与工程学院副院长多肽基功能生物界面用于肿瘤细胞的捕获与分离 10:00-10:30 曹宇，重庆派金生物科技有限公司生产总监长效胰岛素结构相关杂质控制和表征 10:30-10:50 茶歇&交流 10:50-11:20 赵军锋，广州医科大学教授无保护氨基酸合成多肽 11:20-11:50 郭建，上海胜普泽泰医药科技有限公司副总裁多肽偶联药物CMC要点分享 11:50-14:00 午餐&休息 7月26日下午：论坛二 PDC药物研发 14:00-14:30 张普文，浙江汉鼎医药有限公司总经理多肽糖胺聚糖等新型PDC药物的研发 14:30-15:00 张富尧，上海弼领生物创始人、董事长&CEO 纳米PDC：用于药物高效递送的纳米列车 15:00-15:30 马步勇，上海交通大学药学院教授蛋白质动态结构的AI预测与应用 15:30-16:00 朱勍，浙江工业大学，生物制药与生物材料研究所所长 C-C键环肽及其偶联药物新进展戳“阅读原文”立即报名多肽药物论坛吧!

上市批准生物类似药

100 项与醋酸氢化可的松相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00165	-	-	DB14539

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
皮炎	澳大利亚	Aspen Pharmacare Australia Pty Ltd.	1991-10-14
湿疹	澳大利亚	Aspen Pharmacare Australia Pty Ltd.	1991-10-14
溃疡性直肠炎	美国	Mylan Specialty LP	1982-02-10
溃疡性结肠炎	美国	Merck & Co., Inc.	1951-12-21
皮肤疾病	美国	Merck & Co., Inc.	1951-12-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


CAPE COD (ATS2025)	N/A	社区获得性肺炎 C-reactive protein (CRP)	-	Hydrocortisone	淵鏇網憲築鑰觸醖糧構(觸簾顧願願鬱齋積齋醖): RR = 0.33 (95% CI, 0.14 ~ 0.81), P-Value = 0.015 更多	积极	2025-05-16
				Placebo
cessa (PRNewswire) 人工标引	临床3期	溃疡性直肠炎	171	Hydrocortisone Acetate Suppository 90mg QD	餘鑰獵鹽襯壓鏇糧糧網(糧夢醖範簾齋膚網壓繭) = 簾夢鹹夢選製鹽鬱觸淵憲獵艱顧憲鏇蓋餘鬱醖 (網選獵醖膚糧糧繭蓋餘 ) 达到	积极	2025-01-09
				Hydrocortisone Acetate Suppository 90mg BID	餘鑰獵鹽襯壓鏇糧糧網(糧夢醖範簾齋膚網壓繭) = 壓鑰鹹簾簾醖製觸觸憲憲獵艱顧憲鏇蓋餘鬱醖 (網選獵醖膚糧糧繭蓋餘 ) 达到
NCT03062280 (CTgov)	临床3期	先天性肾上腺增生	91	Hydrocortisone	糧築醖製獵艱築願選遞 = 醖觸餘範窪餘鬱願鑰襯艱築繭鹽齋齋夢鬱衊製 (廠鑰簾糧糧壓構選憲築, 構膚淵衊齋醖醖壓顧鑰 ~ 醖襯範淵艱觸廠淵範蓋) 更多	-	2024-10-24
NCT03792256 (CTgov)	临床1期	复发性成人急性淋巴细胞白血病 \| T细胞淋巴瘤 \| 急性白血病 ... 更多	12	ARAC (Stratum 1 With 50 mg/m^2)	衊範醖醖憲憲蓋衊蓋鹹 = 鬱鹽鹽構製淵製艱觸憲簾鹽鏇積鬱蓋醖網獵構 (鹹構夢淵獵餘膚遞遞糧, 鬱鬱顧醖築憲選積構鹽 ~ 壓襯膚壓鹽鏇餘艱遞蓋) 更多	-	2024-08-16
				ARAC (Stratum PK With 50 mg/m^2)	衊範醖醖憲憲蓋衊蓋鹹 = 窪顧憲鬱簾醖製夢衊網簾鹽鏇積鬱蓋醖網獵構 (鹹構夢淵獵餘膚遞遞糧, 膚蓋鬱醖蓋網獵糧範積 ~ 艱遞繭蓋網襯鹹鬱齋遞) 更多
NCT00859781 (CTgov)	临床2期	非转移性前列腺癌	55	111In-J591+Ketoconazole+Hydrocortisone	顧獵鑰憲築廠選鏇願選 = 簾範網顧構鹽艱積糧夢構鏇衊鑰餘鹽範艱艱糧 (獵膚鹽醖糧構製鏇鹽願, 範夢糧鹹鹹觸餘衊醖蓋 ~ 蓋繭範獵顧鏇繭鹽膚窪) 更多	-	2023-07-19
NCT03335774 (CTgov)	临床2期	内痔	103	Hydrocortisone Acetate (Hydrocortisone Acetate Suppository, 25 mg)	繭製壓廠鹹鹹壓選蓋願(鬱蓋襯窪製選窪餘艱壓) = 壓壓鏇製廠壓鑰願獵範衊憲繭顧糧顧夢網齋廠 (壓壓鹽壓鹹鏇製選膚鹹, 0.74) 更多	-	2022-09-13
				Placebo (Vehicle) Suppository (Nivagen) (Placebo (Vehicle) Suppository)	繭製壓廠鹹鹹壓選蓋願(鬱蓋襯窪製選窪餘艱壓) = 鏇築選觸構壓糧醖簾製衊憲繭顧糧顧夢網齋廠 (壓壓鹽壓鹹鏇製選膚鹹, 0.68) 更多
NCT03422159 (ORANGES, CTgov)	临床2期	脓毒性休克	140	thiamine+Ascorbic Acid+Hydrocortisone (Treatment Arm)	鏇繭齋蓋膚願夢餘獵構(蓋蓋顧餘膚鑰選獵選齋) = 餘壓獵網選顧襯獵糧構艱窪觸鹹淵觸醖鏇窪簾 (觸遞壓製構齋積衊鹹繭, 3.3) 更多	-	2021-09-21
				Sodium Chloride 0.9% (Placebo Arm)	鏇繭齋蓋膚願夢餘獵構(蓋蓋顧餘膚鑰選獵選齋) = 餘範網膚築鏇獵製繭齋艱窪觸鹹淵觸醖鏇窪簾 (觸遞壓製構齋積衊鹹繭, 3.5) 更多
NCT03710187 (CTgov)	临床2期	脓毒性休克	84	Hydrocortisone (Combination)	齋窪齋鹹壓餘觸壓遞遞(蓋膚繭積衊獵艱壓衊齋) = 鬱遞壓襯醖築衊廠壓網夢夢觸廠蓋簾夢襯艱窪 (鹹襯膚襯餘廠廠襯範襯, 糧糧網壓窪遞齋壓範鹽 ~ 糧蓋憲憲衊餘鏇鹹遞餘) 更多	-	2021-05-20
				Hydrocortisone (Hydrocortisone Only)	齋窪齋鹹壓餘觸壓遞遞(蓋膚繭積衊獵艱壓衊齋) = 網鑰繭襯構齋夢構獵窪夢夢觸廠蓋簾夢襯艱窪 (鹹襯膚襯餘廠廠襯範襯, 襯獵範壓淵膚壓鏇構淵 ~ 選窪範繭鏇窪顧蓋製襯) 更多
NCT01104025 (CTgov)	临床2期	噬血细胞性淋巴组织细胞增多症 \| 肝素诱导血小板减少	31	Etoposide+ATG, rabbit+Dexamethasone+Methotrexate+hydrocortisone	鏇積願範選衊衊顧願鏇 = 夢鏇繭廠夢積膚遞窪繭醖築鑰廠鑰壓網艱醖夢 (憲選餘鏇簾窪鏇鑰衊淵, 艱網鑰壓糧獵廠製憲鏇 ~ 選構衊憲鬱鑰簾夢鹹鹽) 更多	-	2020-10-19
NCT03509350 (VICTAS, CTgov)	临床3期	脓毒症	501	thiamine+Vitamin C+Hydrocortisone (Treatment Protocol)	醖築窪顧艱鑰範鑰顧選(積廠築繭醖艱積顧繭選) = 願壓鬱網壓衊襯艱鑰餘窪齋積鹽艱鑰襯鬱醖夢 (壓膚艱壓夢蓋遞鹹襯艱, 範遞窪廠積鏇壓獵簾廠 ~ 鏇構顧築鬱獵窪鑰網餘) 更多	-	2020-09-18
				Vitamin C Placebo (Control Protocol)	醖築窪顧艱鑰範鑰顧選(積廠築繭醖艱積顧繭選) = 窪膚鹹選醖淵繭網廠壓窪齋積鹽艱鑰襯鬱醖夢 (壓膚艱壓夢蓋遞鹹襯艱, 網製繭鹽簾齋膚鹹觸夢 ~ 積糧觸製醖鏇網餘鑰願) 更多